Welcome to our dedicated page for Coeptis Therapeutics Holdings news (Ticker: COEP), a resource for investors and traders seeking the latest updates and insights on Coeptis Therapeutics Holdings stock.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company focused on developing cell therapy platforms for patients with cancer, autoimmune, and infectious diseases. The company's product portfolio includes multi-antigen CAR T technology known as SNAP-CAR, CD38-GEAR-NK cell therapy technology, and CD38-Diagnostic in vitro diagnostic for CD38-related cancers. Coeptis has strategic partnerships with Deverra Therapeutics, VyGen-Bio, the University of Pittsburgh, and the Karolinska Institutet to advance its innovative therapies. With a strong emphasis on research and development, Coeptis aims to revolutionize treatment paradigms and improve patient outcomes across various therapeutic areas.
Rhea-AI Summary
Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) announced President and CEO Dave Mehalick's Letter to Shareholders, detailing the exclusive licensing agreement with Deverra Therapeutics Inc, the progress of DVX201 allogeneic NK cell therapy, and the company's vision for developing next-generation cell therapy technologies for cancer and infectious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.65%
Tags
-
Rhea-AI Summary
Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) announced that Dave Mehalick, President and CEO, will deliver a virtual presentation at the Emerging Growth Conference on December 6th, 2023. Coeptis is a biopharmaceutical company developing innovative cell therapy platforms for cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.35%
Tags
-
Rhea-AI Summary
Coeptis Therapeutics announces research demonstrating the potential of the SNAP-CAR T-cell platform to target multiple antigens through combinatorial use of different adaptors. The research shows versatile antigen targeting abilities in vitro and in vivo, including potent and specific function, tumor reduction, and inhibition of tumor growth. The findings suggest the SNAP-CAR platform has vast potential for treating various cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.74%
Tags
Rhea-AI Summary
Coeptis Therapeutics Holdings, Inc. has entered into a definitive agreement for a private placement of 2,000,000 shares of its common stock, with expected gross proceeds of $2,000,000. The company intends to use the net proceeds for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
-
Rhea-AI Summary
Coeptis expands exclusive license agreement with University of Pittsburgh for SNAP-CAR technology platform in NK cells. Also obtains exclusive rights to negotiate acquisition of GEAR™ cell therapy and companion diagnostic platforms from VyGen Bio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
-
Rhea-AI Summary
Coeptis Therapeutics Holdings, Inc. to participate in panel on emerging cell and gene therapies at BioFlorida Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
Rhea-AI Summary
Coeptis Therapeutics announces acceptance of abstract involving SNAP-CAR for presentation at SITC 2023, validating its potential in cancer therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Coeptis Therapeutics Holdings, Inc. announces presentation at 2023 Cell & Gene Meeting on the Mesa. Dr. Delaney to discuss positive safety results for DVX201 in AML, MDS, and COVID-19 patients. Virtual attendance available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.31%
Tags
-
Rhea-AI Summary
Coeptis Therapeutics reports positive safety results for DVX201 cell therapy in Phase 1 trials for AML, MDS, and COVID-19 patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.08%
Tags
Rhea-AI Summary
Deverra Therapeutics receives grants totaling $3.5 million for CAR-NK and myeloid cell programs in cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.29%
Tags
FAQ
What is the current stock price of Coeptis Therapeutics Holdings (COEP)?
The current stock price of Coeptis Therapeutics Holdings (COEP) is $12.08 as of February 4, 2025.
What is the market cap of Coeptis Therapeutics Holdings (COEP)?
The market cap of Coeptis Therapeutics Holdings (COEP) is approximately 27.3M.
What is Coeptis Therapeutics Holdings Inc focused on?
Coeptis is dedicated to developing cell therapy platforms for cancer, autoimmune, and infectious diseases.
What are the key products in Coeptis' portfolio?
The company's product portfolio includes SNAP-CAR multi-antigen CAR T technology, CD38-GEAR-NK cell therapy technology, and CD38-Diagnostic in vitro diagnostic.
Who are some of Coeptis' strategic partners?
Coeptis has strategic partnerships with Deverra Therapeutics, VyGen-Bio, the University of Pittsburgh, and the Karolinska Institutet.
What is Coeptis' goal in their research and development efforts?
Coeptis aims to revolutionize treatment paradigms and improve patient outcomes across various therapeutic areas.
Coeptis Therapeutics Holdings Inc.
Nasdaq:COEP
COEP Rankings
COEP Stock Data
27.31M
2.49M
18.53%
4.28%
0.39%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States of America
WEXFORD